Genome-Wide Mendelian Randomization Reveals Genetically-Supported Drug Targets for Psychiatric Disorders

Xiaoyan Li,Aotian Shen,Junfeng Xia

DOI: https://doi.org/10.2139/ssrn.4204778

2022-01-01

Abstract:Background: Psychiatric disorders impose a huge health and economic burden on modern society. However, there is currently no proven disease-modifying treatment available, partly owing to the inefficiency of drug target identification and validation. Here, we aim to identify therapeutic targets relevant to psychiatric disorders by conduct a Mendelian randomization (MR) analysis.Methods: We performed a genome-wide MR analysis by integrating expression quantitative trait loci (eQTL) of 4,479 actionable genes that encode druggable proteins and genetic summary statistics from genome-wide association studies (GWASs) of psychiatric disorders. Furthermore, we conducted colocalization analysis on the top MR findings (after sensitivity analysis) to confirm the sharing of the same causal variants between gene expression and trait in each genomic region. We then employed protein quantitative trait loci (pQTL) data as genetic proposed instruments for intersected the colocalized genes to provide further genetic evidence.Findings: By focusing on druggable eQTL genetic instruments in MR analysis, we obtained 19 promising drug targets for psychiatric disorders, including 12 significant genes for schizophrenia, four significant genes for bipolar disorder, two significant genes for depression, and one significant gene for attention deficit and hyperactivity. Combining MR results using pQTL genetic instruments, we finally proposed two drug-targeting genes (ACE and NEK4) with schizophrenia, one gene (NEK4) with bipolar disorder, and one gene (TIE1) with attention deficit and hyperactivity, which are supported by the strongest MR evidence. Interpretation: This work revealed that drug-targeting ACE, NEK4 and TIE1 with genetic support were more likely to be to succeed in clinical trials. In addition, our study prioritizes approved drug targets for the development of new therapies and provides critical drug reuse opportunities for psychiatric disorders.Funding: This work was supported by the grant from the National Natural Science Foundation of China (82101611, 11835014, 62072003) and the National Key Research and Development Program of China (2020YFA0908700).Declaration of Interest: There are no conflicts of interest to declare.